Mike has 36 years of experience in the BioPharma industry, having spent 16 years in R&D and 17 years in manufacturing at Merck, retiring as a senior vice president in March of 2022. He then went on to become Head, Pharmaceutical Sciences in R&D at Takeda Pharmaceuticals in September 2022 and retired from Takeda in 2025. At Merck, Mike led process development/new product introduction, operations, facility construction/start-up and divisional strategy/transformation/culture. Under his leadership, Mike’s areas have commercialized products which have changed medical paradigms for treatment including the first effective AIDS therapy and the only single dose vaccine for Ebola, as well as large market drugs like JANUVIA (for Type II diabetes) and KEYTRUDA (oncology) and has overseen more than 50 new product introductions. During his time at Takeda, Mike was for CMC development from the Research interface through introduction to Manufacturing.
In addition, Mike has sponsored over $8BB in new manufacturing facilities, successfully led 3 major transformation/integration projects and was a leader in the application of knowledge management in the CMC arena in the pharmaceutical industry.
Mike received his PhD from MIT, his BS from Caltech. He chairs a hospital board, sits on two Boards of Directors (including the board of Ireland’s NIBRT), and has been a member of or chaired numerous academic visiting committees. He has been a member of AIChE for 41 years and was recently named a Fellow of the AIChE. He is married with two sons and currently lives in Westfield, New Jersey.